These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 22577890)

  • 21. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity.
    Wilhelm SM; Dumas J; Adnane L; Lynch M; Carter CA; Schütz G; Thierauch KH; Zopf D
    Int J Cancer; 2011 Jul; 129(1):245-55. PubMed ID: 21170960
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FDA approves regorafenib (Stivarga) for metastatic colorectal cancer.
    Oncology (Williston Park); 2012 Oct; 26(10):896. PubMed ID: 23175993
    [No Abstract]   [Full Text] [Related]  

  • 23. An overview of experimental and investigational multikinase inhibitors for the treatment of metastatic colorectal cancer.
    Lee YC; Michael M; Zalcberg JR
    Expert Opin Investig Drugs; 2015; 24(10):1307-20. PubMed ID: 26212373
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy Models.
    Daudigeos-Dubus E; Le Dret L; Lanvers-Kaminsky C; Bawa O; Opolon P; Vievard A; Villa I; Pagès M; Bosq J; Vassal G; Zopf D; Geoerger B
    PLoS One; 2015; 10(11):e0142612. PubMed ID: 26599335
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer.
    Jones RL; Bendell JC; Smith DC; Diefenbach K; Lettieri J; Boix O; Lockhart AC; O'Bryant C; Moore KN
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):777-84. PubMed ID: 26281907
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regorafenib: A Review of Its Use in Patients with Advanced Gastrointestinal Stromal Tumours.
    Shirley M; Keating GM
    Drugs; 2015 Jun; 75(9):1009-17. PubMed ID: 25998375
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of the oral multikinase inhibitor regorafenib and its association with real-world treatment outcomes.
    Fukudo M; Asai K; Tani C; Miyamoto M; Ando K; Ueno N
    Invest New Drugs; 2021 Oct; 39(5):1422-1431. PubMed ID: 33830408
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regorafenib in the treatment of colorectal cancer.
    Majithia N; Grothey A
    Expert Opin Pharmacother; 2016; 17(1):137-45. PubMed ID: 26559195
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regorafenib-induced hyperammonemic encephalopathy.
    Kuo JC; Parakh S; Yip D
    J Clin Pharm Ther; 2014 Aug; 39(4):446-8. PubMed ID: 24707992
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regorafenib as a single-agent in the treatment of patients with gastrointestinal tumors: an overview for pharmacists.
    Rey JB; Launay-Vacher V; Tournigand C
    Target Oncol; 2015 Jun; 10(2):199-213. PubMed ID: 25213039
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer.
    Huynh H; Ong R; Zopf D
    J Exp Clin Cancer Res; 2015 Oct; 34():132. PubMed ID: 26514182
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [New molecular-targeted agents for colorectal cancer - regorafenib and aflibercept].
    Kato S
    Gan To Kagaku Ryoho; 2013 Jan; 40(1):6-9. PubMed ID: 23306912
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Regorafenib: A novel tyrosine kinase inhibitor: A brief review of its therapeutic potential in the treatment of metastatic colorectal carcinoma and advanced gastrointestinal stromal tumors.
    Thangaraju P; Singh H; Chakrabarti A
    Indian J Cancer; 2015; 52(3):257-60. PubMed ID: 26905101
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evolution of regorafenib from bench to bedside in colorectal cancer: Is it an attractive option or merely a "me too" drug?
    Goel G
    Cancer Manag Res; 2018; 10():425-437. PubMed ID: 29563833
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Tolerability and efficacy of regorafenib in patients with unresectable metastatic colorectal cancer].
    Tanaka A; Sadahiro S; Suzuki T; Okada K; Saito G
    Gan To Kagaku Ryoho; 2014 Oct; 41(10):1231-6. PubMed ID: 25335705
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regorafenib (Stivarga) for metastatic colorectal cancer and GIST.
    Med Lett Drugs Ther; 2013 Apr; 55(1415):e36. PubMed ID: 23836345
    [No Abstract]   [Full Text] [Related]  

  • 37. Prophylactic Effect of Dexamethasone on Regorafenib-Related Fatigue and/or Malaise: A Randomized, Placebo-Controlled, Double-Blind Clinical Study in Patients with Unresectable Metastatic Colorectal Cancer (KSCC1402/HGCSG1402).
    Tanioka H; Miyamoto Y; Tsuji A; Asayama M; Shiraishi T; Yuki S; Kotaka M; Makiyama A; Shimokawa M; Shimose T; Masuda S; Yamaguchi T; Komatsu Y; Saeki H; Emi Y; Baba H; Oki E; Maehara Y;
    Oncology; 2018; 94(5):289-296. PubMed ID: 29514163
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evolving role of regorafenib for the treatment of advanced cancers.
    Grothey A; Blay JY; Pavlakis N; Yoshino T; Bruix J
    Cancer Treat Rev; 2020 Jun; 86():101993. PubMed ID: 32199197
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of the multikinase inhibitors Sorafenib and Regorafenib in PTEN deficient neoplasias.
    Mirantes C; Dosil MA; Eritja N; Felip I; Gatius S; Santacana M; Matias-Guiu X; Dolcet X
    Eur J Cancer; 2016 Aug; 63():74-87. PubMed ID: 27288872
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Regorafenib approved in Metastatic Colorectal cancer].
    André T; Dumont SN
    Bull Cancer; 2013 Oct; 100(10):1027-9. PubMed ID: 24047557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.